Public combat over US drug prices centers on Prop 61 as rhetoric heats up to fever pitch
A week ago, Proposition 61 looked like a sure winner for its advocates. With sentiment running strongly against Big Pharma companies, polls showed plenty of support for a ballot measure in California that would cap drug prices for the state at the level that the Veterans Administration reaches through price negotiations.
But with the vote now just hours away, the industry is seeing the polling results leaning to a dead heat after throwing more than $100 million into the fight, which is reaching a fever pitch in the hours before final voting begins.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
